NexgenRx Inc (TSE:NXG) has released an update.
NexgenRx Inc. reported a robust first quarter in 2024, showcasing a 24% increase in revenue to $4.3 million and substantial growth in net income and EBITDA, attributed to the successful introduction of SaaS solutions and a strong sales pipeline. The company celebrated its 20th anniversary with a record Q1 performance and a solid cash position, even after a significant dividend payout to shareholders.
For further insights into TSE:NXG stock, check out TipRanks’ Stock Analysis page.
